Despite advances in cancer treatment, primary bone tumors have seen no new therapies in over 20 years, leaving inoperable cases with extremely limited options. For metastatic bone tumors, current treatments fail to directly control bone metastases, resulting in fractures and pain that significantly reduce quality of life. Surv BioPharma is developing innovative oncolytic virus therapy to address these unmet medical needs. The company's platform technology aims to extend survival for primary bone tumor patients while preserving motor function and improving clinical outcomes for those with bone metastases. By expanding treatment options for previously untreatable conditions, the company addresses critical gaps in oncology care.